<DOC>
	<DOCNO>NCT00395967</DOCNO>
	<brief_summary>This Phase 2 study design ass safety hematological activity AMD3100 ( plerixafor ) patient non-Hodgkin 's lymphoma ( NHL ) multiple myeloma ( MM ) predict unable mobilize ≥2*10^6 CD34+ cells/kg within 3 apheresis day . Patients NHL MM eligible enter study undergone cyto-reductive chemotherapy , undergo autologous transplantation , meet inclusion/exclusion criterion . The purpose protocol determine whether plerixafor combination Granulocyte Colony Stimulating Factor ( G-CSF ) increase circulating level peripheral blood stem cell ( PBSCs ) patient whose peripheral CD34+ count remain low treatment G-CSF alone , whether safe , whether transplantation apheresis product successful , measured time engraftment polymorphonuclear leukocyte ( PMNs ) platelet ( PLTs ) .</brief_summary>
	<brief_title>AMD3100 ( Plerixafor ) Multiple Myeloma ( MM ) Non-Hodgkin 's Lymphoma ( NHL ) Patients Predicted Unable Mobilize With G-CSF Alone</brief_title>
	<detailed_description>A Phase 2 , single-center , open-label study ass safety hematological activity plerixafor patient non-Hodgkin 's lymphoma ( NHL ) multiple myeloma ( MM ) predict unable mobilize ≥2*10^6 CD34+ cells/kg within 3 apheresis day . The change standard care addition plerixafor G-CSF mobilization regimen day prior apheresis . Following screening procedure , eligible patient undergo mobilization G-CSF ( 10 µg/kg every day ) 5 day peripheral blood ( PB ) CD34+ cell count measure fifth day . On Day 5 , patient 's peripheral CD34+ cell count &lt; 5 cells/µl ≥20 cells/µl , patient enter study treat per policy study site . On Day 5 , patient 's peripheral CD34+ cell count 5 7 cells/µl ( inclusive ) , patient undergo apheresis day , receive plerixafor ( 240 µg/kg ) even G-CSF follow apheresis next morning . The evening dose plerixafor follow next morning G-CSF apheresis repeat total 3 day apheresis ≥5*10^6 cells/kg collect . On Day 5 , patient 's peripheral CD34+ cell count 8 19 cells/µl ( inclusive ) , he/she underwent apheresis day . If apheresis yield &lt; 1.3*10^6 CD34+ cells/kg , patient predict unlikely collect ≥2*10^6 CD34+ cells/kg ≥3 day apheresis receive plerixafor ( 240 µg/kg ) evening . However , apheresis yield Day 5 ≥1.3*10^6 CD34+ cells/kg , patient enter study . The next morning ( Day 6 ) , eligible patient receive G-CSF ( 10 µg/kg ) begin apheresis approximately 10 11 hour previous even plerixafor dose . If apheresis yield least double apheresis yield Day 5 , patient receive another 10:00 pm dose plerixafor underwent apheresis next morning ( Day 7 ) receive G-CSF . The evening dose plerixafor follow next morning G-CSF apheresis repeat total 3 day apheresis ≥5*10^6 cells/kg collect . All patient , completion apheresis procedure ( ≥5*10^6 cells/kg collect ) , receive high-dose chemotherapy preparation transplantation . Patients transplant cell collect receive plerixafor G-CSF . However , insufficient cell , cell collect receive plerixafor G-CSF could pool cell collect receive G-CSF alone . Hematological activity plerixafor evaluate assess number CD34+ cell harvest apheresis . This study previously post AnorMED , Inc . In November 2006 , AnorMED , Inc. acquire Genzyme Corporation . Genzyme Corporation sponsor trial .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Inclusion Criteria ( Abbreviated List ) : Diagnosis nonHodgkin 's lymphoma ( NHL ) multiple myeloma ( MM ) Eligible autologous transplantation &lt; =3 prior regimens chemotherapy ( Rituxan consider chemotherapy purpose study ) &gt; 4 week since last cycle chemotherapy ( Rituxan consider chemotherapy purpose study ) Total dose melphalan ≦200 mg Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 White blood cell ( WBC ) count &gt; 3.0*10^9/L prior first dose GCSF Absolute polymorphonuclear leukocyte ( PMN ) count &gt; 1.5*10^9/L prior first dose GCSF Platelet ( PLT ) count &gt; 100*10^9/L prior first dose granulocyte colonystimulating factor ( GCSF ) Serum creatinine ≥2.2 mg/dL SGOT , SGPT total bilirubin &lt; 2 time upper limit normal ( ULN ) Negative HIV CD34+ cell count 5 19 CD34+ cells/ml 5 day mobilization GCSF alone Exclusion Criteria ( Abbreviated List ) : A comorbid condition , view investigator , render patient high risk treatment complication Failed previous stem cell collection collection attempt A residual acute medical condition result prior chemotherapy Active brain metastasis carcinomatous meningitis Active infection require antibiotic treatment Received prior radioimmunotherapy Zevalin Bexxar Received boneseeking radionuclides ( e.g. , holmium ) Received thalidomide , dexamethasone , and/or Velcade within 7 day prior first dose GCSF History ventricular arrhythmia , include electrocardiogram ( ECG ) document premature ventricular contraction ( PVCs ) , last 3 year Patients previously receive experimental therapy within 4 week enrol protocol currently enrol another experimental protocol mobilization phase Had apheresis yield &gt; 1.3*10^6 CD34+ cells/kg Day 5 ( Applicable patient , 5 day GCSF mobilization , peripheral blood ( PB ) CD34+ count 819 cells/µl inclusive ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>stem cell mobilization</keyword>
	<keyword>autologous transplantation</keyword>
	<keyword>AMD3100</keyword>
</DOC>